Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. J Clin Invest 1987 Jun;79(6):1642-7
Date
06/01/1987Pubmed ID
2953761Pubmed Central ID
PMC424490DOI
10.1172/JCI113001Scopus ID
2-s2.0-0023195775 (requires institutional sign-in at Scopus site) 44 CitationsAbstract
We have determined the extent of fragment X formation during thrombolytic therapy by integration over time of the plasma fibrinopeptide B beta 1-42 concentration. This peptide is quantitatively released when fragment X is formed by plasmin action on fibrinogen or fibrin I. In response to streptokinase (SK) and rt-PA, 264 +/- 54 and 95 +/- 12 mg/dl respectively of fibrinogen was converted to fragment X. By immunoblotting, fragment X was demonstrated as early as 5 min after SK and 30 min after rt-PA, and was still evident 24 h after treatment. Patients treated with SK showed extensive further plasmin degradation of fragment X to fragments Y and D. Thus fragment X concentrations tend to be more similar in the two groups than would be expected from the extent of fibrinogen breakdown. Fragment X forms clots, but these have lower tensile strength and are more susceptible to further plasmin lysis than clots of fibrin. Thus the similar bleeding observed in the two treatment groups might be a reflection of their similar plasma fragment X concentrations.
Author List
Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ERAuthor
Kenneth D. Friedman MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Fibrin Fibrinogen Degradation ProductsFibrinolysin
Fibrinolytic Agents
Fibrinopeptide B
Hemorrhagic Disorders
Humans
Myocardial Infarction
Recombinant Proteins
Streptokinase
Tissue Plasminogen Activator
